Compare CRBP & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBP | AEI |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 119.4M |
| IPO Year | 2014 | 2019 |
| Metric | CRBP | AEI |
|---|---|---|
| Price | $10.10 | $1.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $45.60 | N/A |
| AVG Volume (30 Days) | ★ 201.7K | 16.1K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,822,272.00 | ★ $16,238,200.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $4.64 | $0.70 |
| 52 Week High | $20.56 | $4.55 |
| Indicator | CRBP | AEI |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 43.23 |
| Support Level | $9.86 | $1.47 |
| Resistance Level | $11.64 | $2.11 |
| Average True Range (ATR) | 0.69 | 0.20 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 83.54 | 29.42 |
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.